NASDAQ | TSX: ACB
Bidiol is the only full-spectrum cannabis
oil that is fully produced domestically
EDMONTON, AB, Sept. 29, 2021 /PRNewswire/ - Aurora Cannabis
Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company
defining the future of cannabinoids worldwide, has launched Bidiol,
the first medical cannabis oil in Uruguay that is wholly produced domestically.
The CBD oil is available in 3% and 10% concentrations and comes in
10mL and 30mL bottles, available in pharmacies across the
country.
"The launch of Bidiol has been two years in the making and is an
integral part of our renewed strategy in Uruguay," said Miguel
Martin, Chief Executive Officer of Aurora Cannabis. "We have
prioritized key international markets with the potential to
meaningfully expand their patient base. Our efforts include working
alongside governments and local partners to do what works best in
each market. There isn't a one size fits all strategy – our
approach must be smart and domestically relevant."
A leader in the international cannabis market, Aurora has
shifted its strategy in Uruguay to
focus exclusively on medical cannabis, with the aim of making the
country its continental centre of production and distribution.
Aurora's operation in Uruguay
includes one of the only GMP certified cannabis processing
facilities in the country.
CBD oil is authorized by the Ministry of Public Health of
Uruguay for the treatment of
refractory epilepsy in children and adolescents.
Aurora is continuing to develop its CBD oil product line in
Uruguay, with plans to expand its
portfolio in the coming months.
About Aurora:
Aurora is a global leader in the cannabis industry, serving
both the medical and consumer markets. Headquartered in
Edmonton, Alberta, Aurora is a
pioneer in global cannabis dedicated to helping people improve
their lives. The Company's brand portfolio includes
Aurora, Aurora Drift, San Rafael '71, Daily
Special, MedReleaf, CanniMed, Whistler, Reliva and KG7
CBD. Driven by science and innovation, and with a focus on
high-quality cannabis products, Aurora's brands continue to break
through as industry leaders in the medical, performance,
wellness and adult recreational markets
wherever they are launched. Learn more
at www.auroramj.com and follow us
on Twitter and LinkedIn.
Aurora's common shares trade on the TSX
and NASDAQ under the symbol "ACB" and is a constituent of
the S&P/TSX Composite Index.
Forward-looking Information
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. Forward-looking statements made in this news
release include statements regarding the launch of new
products and availability of the products at pharmacies in
Uruguay. These forward-looking
statements are only predictions. Various assumptions were used in
drawing the conclusions or making the projections contained in the
forward-looking statements throughout this news release. Forward
looking statements are based on the opinions, estimates and
assumptions of management in light of management's experience and
perception of historical trends, current conditions and expected
developments at the date the statements are made, such as current
and future market conditions, the ability to maintain SG&A
costs in line with current expectations, the ability to achieve
high margin revenues in the Canadian consumer market, the current
and future regulatory environment and future approvals and permits.
Forward-looking statements are subject to a variety of risks,
uncertainties and other factors that management believes to be
relevant and reasonable in the circumstances could cause actual
events, results, level of activity, performance, prospects,
opportunities or achievements to differ materially from those
projected in the forward-looking statements, including the risks
associated with: entering the U.S. market, the ability to realize
the anticipated benefits associated with the acquisition of Reliva,
achievement of Aurora's business transformation plan, general
business and economic conditions, changes in laws and regulations,
product demand, changes in prices of required commodities,
competition, the effects of and responses to the COVID-19 pandemic
and other risks, uncertainties and factors set out under the
heading "Risk Factors" in the Company's annual information form
dated September 27, 2021 (the "AIF")
and filed with Canadian securities regulators available on the
Company's issuer profile on SEDAR at www.sedar.com and filed with
and available on the SEC's website at www.sec.gov. The Company
cautions that the list of risks, uncertainties and other factors
described in the AIF is not exhaustive and other factors could also
adversely affect its results. Readers are urged to consider the
risks, uncertainties and assumptions carefully in evaluating the
forward-looking statements and are cautioned not to place undue
reliance on such information. The Company is under no obligation,
and expressly disclaims any intention or obligation, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as expressly
required by applicable securities law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-launches-its-first-medical-cbd-product-in-uruguay-301388208.html
SOURCE Aurora Cannabis Inc.